Connect your AI

Haemonetics HAE Operating Cash Flow

Operating Cash Flow at other companies

AbbottABT

$1.32B-7.2%

TFX

TeleflexTFX

$46.66M+68.3%

Boston ScientificBSX

$348M-35.7%

MedtronicMDT

$2.57B+1.8%

LivaNovaLIVN

$15.22M-36.5%

ICU MedicalICUI

$38.91M-24.2%

Other financials

Income statement

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

Market cap$3.37B-18.0%

Enterprise value$4.4B-12.5%

P/S2.5×-0.5×

Profitability

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Haemonetics's operating cash flow?: Haemonetics (HAE) reported operating cash flow of $70.94M in Q1 2026.
How has Haemonetics's operating cash flow changed year-over-year?: Haemonetics's operating cash flow decreased by 39.1% year-over-year, from $116.56M to $70.94M.
What is the long-term trend for Haemonetics's operating cash flow?: Over 4 years (2022 to 2026), Haemonetics's operating cash flow has grown at a 14.2% compound annual growth rate (CAGR), from $172.26M to $293.22M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.